$9.54
0.42% yesterday
NYSE, Sep 03, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX

Amneal Pharmaceuticals, Inc. Class A Stock price

$9.54
+1.58 19.85% 1M
+0.78 8.90% 6M
+1.62 20.45% YTD
+1.05 12.37% 1Y
+7.34 333.64% 3Y
+5.81 155.76% 5Y
-30.77 76.33% 10Y
+4.87 104.28% 20Y
NYSE, Closing price Wed, Sep 03 2025
-0.04 0.42%
ISIN
US03168L1052
Symbol
AMRX
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$5.5b
Net debt
$2.5b
Cash
$71.5m
Shares outstanding
314.0m
Valuation (TTM | estimate)
P/E
958.0 | 12.6
P/S
1.1 | 1.0
EV/Sales
1.9 | 1.8
EV/FCF
20.9
P/B
negative
Financial Health
Equity Ratio
-3.1%
Return on Equity
107.0%
ROCE
16.4%
ROIC
9.2%
Debt/Equity
-22.5
Financials (TTM | estimate)
Revenue
$2.9b | $3.1b
EBITDA
$625.2m | $680.1m
EBIT
$379.8m | $560.7m
Net Income
$3.4m | $238.6m
Free Cash Flow
$261.6m
Growth (TTM | estimate)
Revenue
47.2% | 9.6%
EBITDA
40.9% | 16.3%
EBIT
73.9% | 60.9%
Net Income
104.1% | 304.2%
Free Cash Flow
48.6%
Margin (TTM | estimate)
Gross
37.7%
EBITDA
21.9% | 22.2%
EBIT
13.3%
Net
0.1% | 7.8%
Free Cash Flow
9.2%
More
EPS
$0.0
FCF per Share
$0.8
Short interest
2.4%
Employees
8k
Rev per Employee
$340.0k
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
90%
Hold
10%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,853 2,853
47% 47%
100%
- Direct Costs 1,778 1,778
40% 40%
62%
1,075 1,075
60% 60%
38%
- Selling and Administrative Expenses 498 498
46% 46%
17%
- Research and Development Expense 203 203
65% 65%
7%
625 625
41% 41%
22%
- Depreciation and Amortization 245 245
9% 9%
9%
EBIT (Operating Income) EBIT 380 380
74% 74%
13%
Net Profit 3.38 3.38
104% 104%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Positive
The Motley Fool
29 days ago
Amneal (AMRX) Q2 EPS Jumps 56%
Neutral
Seeking Alpha
29 days ago
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investor Relations Chintu Patel - Co-Founder, Co-CEO & Director Chirag K.
Neutral
GlobeNewsWire
30 days ago
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for CREXONT® to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson's disease...
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today